The MR vaccine is a vaccine that protects against measles and rubella. Two doses are usually given at least one month apart. In countries where measles cases are higher, the first dose is recommended at 9 months of age. In other countries it is typically offered between 12 and 15 months of age. In children at high risk of severe measles, the vaccine can be given at 6 months of age with a second dose at 9 months. It is given by injection under the skin.
Side effects are generally mild, temporary and except for allergic reaction are less likely after the second dose. Redness, swelling and pain can occur at the site of injection. A fever may occur typicallybetween 7 and 12 days after a dose. Between 7 and 10 days after a dose, a rash may appear, typically lasting around 2 days. Rare side effects include bruising due to low platelets and an allergic reaction. The vaccine is not recommended in pregnancy, but if inadvertently given, has not been shown to cause harm to the baby. If planning a pregnancy, then it is best to wait at least a month after a dose. It is not safe to give to people with a severely weakened immune system.
Mumps has not been targeted for global elimination, and the MR vaccine is preferred in countries where mumps is not a priority. The MR vaccine was introduced in India in 2017 as part of a mass campaign to eliminate measles and CRS caused by rubella. Around 150 million doses of an Indian-made MR vaccine are available globally, except in Europe. Until given, the vaccine should be kept cold but not frozen.
- ↑ 1.0 1.1 1.2 Vesikari, Timo; Usonis, Vytautas (2021). "9. Measles-Mumps-Rubella vaccine". In Vesikari, Timo; Damme, Pierre Van (eds.). Pediatric Vaccines and Vaccinations: A European Textbook (Second ed.). Switzerland: Springer. p. 83. ISBN 978-3-030-77172-0. Archived from the original on 2022-02-02. Retrieved 2022-02-02.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 Model insert: Measles and Rubella (MR) combined vaccine (PDF). World Health Organization. December 2005. Archived (PDF) from the original on 2022-01-19. Retrieved 2022-02-02.
- ↑ "Serum Institute Of India - MR-Vac - Measles & Rubella Vaccine (Live) I.P." www.seruminstitute.com. Archived from the original on 20 April 2021. Retrieved 2 February 2022.
- ↑ "India's measles-rubella vaccination campaign a big step towards reducing childhood mortality, addressing birth defects". www.who.int. Archived from the original on 3 February 2022. Retrieved 3 February 2022.
- Pages using duplicate arguments in template calls
- Articles using infobox templates with no data rows
- Infobox drug articles with non-default infobox title
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Infobox drug articles without vaccine target
- Articles containing unverified chemical infoboxes
- Drugs that are a vaccine
- Portal templates with all redlinked portals
- Combination vaccines
- Live vaccines